IOV-5001 for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests an investigational cell therapy, IOV-5001, in adults with certain advanced cancers (lung, breast, colorectal, or head and neck). The therapy uses a patient's own immune cells to target the tumor, and the study aims to see if it can slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have one of these cancers: stage IV non-small cell lung cancer (without certain gene mutations), stage IV or unresectable breast cancer, stage IV colorectal cancer, or stage III/IV head and neck cancer that cannot be cured by standard treatment.
- Your cancer has gotten worse after your most recent treatment.
- You have had certain prior treatments depending on your cancer type (for example, lung cancer: chemotherapy and immunotherapy; breast cancer: at least one chemotherapy; colorectal cancer: certain combinations; head and neck: immunotherapy and platinum chemo unless you can't take platinum).
- You have a tumor lesion that can be removed for the therapy, and you are in generally good health (able to care for yourself, expected to live more than 6 months).
- You do not have untreated brain symptoms, active infections, weakened immune system, or recent live vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This trial tests an experimental therapy that combines a new drug (OVV-01) given intravenously and injected directly into tumors, along with another immunotherapy drug (AK112). It's for people with advanced solid tumors who have run out of standard options, and it aims to see if the combination can shrink tumors or slow their growth.
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
This trial tests an experimental virus-based treatment for people with advanced solid tumors that have stopped responding to standard therapies. The treatment is designed to infect and destroy cancer cells while boosting the immune system.
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.